Arkolith/Insider Trading/BBIO/Form 4

Kumar Neil

Chief Executive Officer, DirectorBridgeBio Pharma, Inc. (BBIO) · full profile →Form 4 · filed Jun 8, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$5.4M
Net Open-Market Flow
-$5.4M
Transactions
14
14 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 5, 2026Sell(S)7K$67.20$480K529K
Jun 5, 2026Sell(S)8K$67.88$573K520K
Jun 5, 2026Sell(S)4K$68.96$305K516K
Jun 5, 2026Sell(S)7K$67.20$480K4.3M
Jun 5, 2026Sell(S)8K$67.88$573K4.3M
Jun 5, 2026Sell(S)4K$68.96$304K4.3M
Jun 4, 2026Sell(S)16K$67.74$1.1M4.3M
Jun 4, 2026Sell(S)2K$65.72$145K553K
Jun 4, 2026Sell(S)450$68.27$31K4.3M
Jun 4, 2026Sell(S)1K$66.72$95K552K
Jun 4, 2026Sell(S)16K$67.74$1.1M536K
Jun 4, 2026Sell(S)450$68.27$31K536K
Jun 4, 2026Sell(S)2K$65.72$145K4.4M
Jun 4, 2026Sell(S)1K$66.72$95K4.4M

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001470831-26-000523) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML